Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT

Main Article Content

Zafer Akan
Hasan Demiroglu
Ugur Avcibasi
Gokhan Oto
Hulya Ozdemir
Sabahattin Deniz
Ali Sadi Basak


Objective: Boron neutron capture therapy (BNCT) is an intensive research area for cancer researchers. Especially the side effects and inabilities of conventional therapies in some cases, directs researchers to find out a new cancer therapy methods such as BNCT. One of three important problem of BNCT is targeting of boron to tumor tissue. Borono Phenyl Alanine (BPA) and Borono Sodium Borocaptate (BSH) are already using in clinical studies as boron carriers. New boron carriers are searching for high yield boron accumulation in the tumor tissue.

Methods: In this study, a novel 10B carrier was synthesized, ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid (10B-DG), for BNCT studies. 10Boric Acid and 2-Deoxy-d-Glucose was complexed (10B-DG) through a low-high pH reaction and yield of complexion was tested with FTIR ATR and Liquid Chromatography Mass Spectrometry (LC/MS).

Results: Confirmation studies have been carried out by HPLC and chromatograms have confirmed that Borono-2-Deoxy-d-Glucose synthesized with % 80 yield.

Conclusions: This compound appears to be an alternative boron carrier for BNCT applications


Download data is not yet available.

Article Details

How to Cite
Akan, Z. ., Demiroglu, H. ., Avcibasi, U. ., Oto, G., Ozdemir, H. ., Deniz, S. ., & Basak, A. S. . (2014). Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT. Medical Science and Discovery, 1(3), 65–71. Retrieved from
Research Article


van Vulpen M, van den Bosch MA, Verkooijen HM, Lagendijk JJ. [Developments in radiotherapy: image-guided and minimally invasive]. Nederlands tijdschrift voor geneeskunde. 2013;157(26):A5857.

Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, et al. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anti-cancer agents in medicinal chemistry. 2006;6(2):167-84.

Dwarakanath BS. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. Journal of cancer research and therapeutics. 2009;5 Suppl 1:S27-31.

Peak D, Luther GW, Sparks DL. Boric acid and borate adsorption mechanisms on amorphous iron oxides: An in situ ATR-FTIR spectroscopic study. Geochimica et Cosmochimica Acta. 2003 67:14,2551-2560.

Cotton FA, Wilkinson G. Advanced Inorganic Chemistry. New York, Wiley. 1980.

Shao C, Matsuoka S, Miyazaki Y. Studies on the Complexation of Boric Acid with Polyhydroxyl Compounds. Analytical Sciences, vol:17, supplement. 2001.

Girard JM, Deschenes JS, Tremblay R, Gagnon J. FT-IR/ATR univariate and multivariate calibration models for in situ monitoring of sugars in complex microalgal culture media. Bioresource technology. 2013;144:664-8.

Cohen-Jonathan Moyal E. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2009;13:562-7.

Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-46.

Wick AN, Drury DR, Nakada HI, Wolfe JB. Localization of the primary metabolic block produced by 2-deoxyglucose. The Journal of biological chemistry. 1957;224(2):963-9.

Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2013;71(2):523-30.

Coleman RE. Clinical PET in Oncology. Clinical positron imaging : official journal of the Institute for Clinical PET. 1998;1(1):15-30.

Yu S. Review of F-FDG Synthesis and Quality Control. Biomedical imaging and intervention journal. 2006;2(4):e57.

Most read articles by the same author(s)